Prelude Therapeutics Incorporated
PRLD Real Time Price USDRecent trades of PRLD by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by PRLD's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Cdk inhibitors and their use as pharmaceuticals Oct. 29, 2024
-
Patent Title: Cdk inhibitors and their use as pharmaceuticals Mar. 26, 2024
-
Patent Title: Brm targeting compounds and associated methods of use Jul. 18, 2023
-
Patent Title: Cdk inhibitors and their use as pharmaceuticals Jun. 27, 2023
-
Patent Title: Cdk inhibitors and their use as pharmaceuticals Jun. 13, 2023
-
Patent Title: Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (prmt5) Dec. 13, 2022
-
Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Feb. 22, 2022
-
Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Jan. 11, 2022
-
Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Jan. 04, 2022
-
Patent Title: Selective inhibitors of protein arginine methytransterase 5 (prmt5) Dec. 28, 2021
-
Patent Title: Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein Sep. 28, 2021
-
Patent Title: Selective inhibitors of protein arginine methlytransferase 5 (prmt5) Aug. 03, 2021
-
Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Jul. 14, 2020
-
Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Feb. 25, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of PRLD in WallStreetBets Daily Discussion
Recent insights relating to PRLD
Recent picks made for PRLD stock on CNBC
ETFs with the largest estimated holdings in PRLD
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PRLD Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.